-
Je něco špatně v tomto záznamu ?
Modern Management of Cardiometabolic Continuum: From Overweight/Obesity to Prediabetes/Type 2 Diabetes Mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group
A. Janez, E. Muzurovic, P. Bogdanski, L. Czupryniak, L. Fabryova, Z. Fras, C. Guja, M. Haluzik, P. Kempler, N. Lalic, D. Mullerova, AP. Stoian, N. Papanas, D. Rahelic, J. Silva-Nunes, T. Tankova, V. Yumuk, M. Rizzo
Status neindexováno Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, přehledy
NLK
Directory of Open Access Journals
od 2010
Free Medical Journals
od 2010
PubMed Central
od 2010
Europe PubMed Central
od 2010
ProQuest Central
od 2010-08-01
Open Access Digital Library
od 2010-01-01
Open Access Digital Library
od 2010-01-01
Nursing & Allied Health Database (ProQuest)
od 2010-08-01
Health & Medicine (ProQuest)
od 2010-08-01
Family Health Database (ProQuest)
od 2010-08-01
Public Health Database (ProQuest)
od 2010-08-01
ROAD: Directory of Open Access Scholarly Resources
od 2010
Springer Journals Complete - Open Access
od 2010-08-01
Springer Nature OA/Free Journals
od 2010-08-01
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
The increasing global incidence of obesity and type 2 diabetes mellitus (T2D) underscores the urgency of addressing these interconnected health challenges. Obesity enhances genetic and environmental influences on T2D, being not only a primary risk factor but also exacerbating its severity. The complex mechanisms linking obesity and T2D involve adiposity-driven changes in β-cell function, adipose tissue functioning, and multi-organ insulin resistance (IR). Early detection and tailored treatment of T2D and obesity are crucial to mitigate future complications. Moreover, personalized and early intensified therapy considering the presence of comorbidities can delay disease progression and diminish the risk of cardiorenal complications. Employing combination therapies and embracing a disease-modifying strategy are paramount. Clinical trials provide evidence confirming the efficacy and safety of glucagon-like peptide 1 receptor agonists (GLP-1 RAs). Their use is associated with substantial and durable body weight reduction, exceeding 15%, and improved glucose control which further translate into T2D prevention, possible disease remission, and improvement of cardiometabolic risk factors and associated complications. Therefore, on the basis of clinical experience and current evidence, the Eastern and Southern Europe Diabetes and Obesity Expert Group recommends a personalized, polymodal approach (comprising GLP-1 RAs) tailored to individual patient's disease phenotype to optimize diabetes and obesity therapy. We also expect that the increasing availability of dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) agonists will significantly contribute to the modern management of the cardiometabolic continuum.
Catholic University of Croatia School of Medicine Zagreb Croatia
Department of Diabetology and Internal Medicine Medical University of Warsaw Warszawa Poland
Department of Endocrinology Diabetes and Metabolism Unidade Local de Saúde São José Lisbon Portugal
Department of Endocrinology Faculty of Medicine Medical University Sofia Bulgaria
Department of Medicine and Oncology Semmelweis University Budapest Hungary
Josip Juraj Strossmayer University of Osijek School of Medicine Osijek Croatia
NOVA Medical School New University of Lisbon Lisbon Portugal
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24017929
- 003
- CZ-PrNML
- 005
- 20241016082027.0
- 007
- ta
- 008
- 241008s2024 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s13300-024-01615-5 $2 doi
- 035 __
- $a (PubMed)38990471
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Janez, Andrej $u Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Center Ljubljana, Ljubljana, Slovenia. andrej.janez@kclj.si $1 https://orcid.org/0000000265945254
- 245 10
- $a Modern Management of Cardiometabolic Continuum: From Overweight/Obesity to Prediabetes/Type 2 Diabetes Mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group / $c A. Janez, E. Muzurovic, P. Bogdanski, L. Czupryniak, L. Fabryova, Z. Fras, C. Guja, M. Haluzik, P. Kempler, N. Lalic, D. Mullerova, AP. Stoian, N. Papanas, D. Rahelic, J. Silva-Nunes, T. Tankova, V. Yumuk, M. Rizzo
- 520 9_
- $a The increasing global incidence of obesity and type 2 diabetes mellitus (T2D) underscores the urgency of addressing these interconnected health challenges. Obesity enhances genetic and environmental influences on T2D, being not only a primary risk factor but also exacerbating its severity. The complex mechanisms linking obesity and T2D involve adiposity-driven changes in β-cell function, adipose tissue functioning, and multi-organ insulin resistance (IR). Early detection and tailored treatment of T2D and obesity are crucial to mitigate future complications. Moreover, personalized and early intensified therapy considering the presence of comorbidities can delay disease progression and diminish the risk of cardiorenal complications. Employing combination therapies and embracing a disease-modifying strategy are paramount. Clinical trials provide evidence confirming the efficacy and safety of glucagon-like peptide 1 receptor agonists (GLP-1 RAs). Their use is associated with substantial and durable body weight reduction, exceeding 15%, and improved glucose control which further translate into T2D prevention, possible disease remission, and improvement of cardiometabolic risk factors and associated complications. Therefore, on the basis of clinical experience and current evidence, the Eastern and Southern Europe Diabetes and Obesity Expert Group recommends a personalized, polymodal approach (comprising GLP-1 RAs) tailored to individual patient's disease phenotype to optimize diabetes and obesity therapy. We also expect that the increasing availability of dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) agonists will significantly contribute to the modern management of the cardiometabolic continuum.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Muzurovic, Emir $u Department of Internal Medicine, Endocrinology Section, Clinical Centre of Montenegro, Faculty of Medicine, University of Montenegro, Podgorica, Montenegro
- 700 1_
- $a Bogdanski, Pawel $u Department of Treatment of Obesity, Metabolic Disorders and Clinical Dietetics, University of Medical Sciences, Poznan, Poland
- 700 1_
- $a Czupryniak, Leszek $u Department of Diabetology and Internal Medicine, Medical University of Warsaw, Warszawa, Poland
- 700 1_
- $a Fabryova, Lubomira $u MetabolKLINIK sro, Department for Diabetes and Metabolic Disorders, Lipid Clinic, MED PED Centre, Biomedical Research Centre of Slovak Academy of Sciences, Slovak Health University, Bratislava, Slovak Republic
- 700 1_
- $a Fras, Zlatko $u Preventive Cardiology Unit, Division of Medicine, University Medical Centre Ljubljana and Chair of Internal Medicine, Medical Faculty, University of Ljubljana, Ljubljana, Slovenia
- 700 1_
- $a Guja, Cristian $u Clinic of Diabetes, Nutrition and Metabolic Diseases, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania
- 700 1_
- $a Haluzik, Martin $u Diabetes Centre, Institute for Clinical and Experimental Medicine, Vídeňská 1958/9, 140 21, Prague 4, Czech Republic
- 700 1_
- $a Kempler, Peter $u Department of Medicine and Oncology, Semmelweis University, Budapest, Hungary
- 700 1_
- $a Lalic, Nebojsa $u Faculty of Medicine, Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Center of Serbia, University of Belgrade, Belgrade, Serbia
- 700 1_
- $a Mullerova, Dana $u Faculty of Medicine in Pilsen, Department of Public Health and Preventive Medicine and Faculty Hospital in Pilsen, 1st Internal Clinic, Charles University, Pilsen, Czech Republic
- 700 1_
- $a Stoian, Anca Pantea $u Diabetes, Nutrition and Metabolic Diseases Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
- 700 1_
- $a Papanas, Nikolaos $u Diabetes Centre, Second Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, Greece
- 700 1_
- $a Rahelic, Dario $u Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases, Merkur University Hospital, Zagreb, Croatia $u Catholic University of Croatia School of Medicine, Zagreb, Croatia $u Josip Juraj Strossmayer, University of Osijek School of Medicine, Osijek, Croatia
- 700 1_
- $a Silva-Nunes, José $u NOVA Medical School, New University of Lisbon, Lisbon, Portugal $u Department of Endocrinology, Diabetes and Metabolism, Unidade Local de Saúde São José, Lisbon, Portugal
- 700 1_
- $a Tankova, Tsvetalina $u Department of Endocrinology, Faculty of Medicine, Medical University, Sofia, Bulgaria
- 700 1_
- $a Yumuk, Volkan $u Division of Endocrinology, Metabolism and Diabetes, Istanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty, Istanbul, Turkey
- 700 1_
- $a Rizzo, Manfredi $u Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (Promise), School of Medicine, University of Palermo, Palermo, Italy
- 773 0_
- $w MED00194311 $t Diabetes therapy $x 1869-6953 $g Roč. 15, č. 9 (2024), s. 1865-1892
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38990471 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241008 $b ABA008
- 991 __
- $a 20241016082023 $b ABA008
- 999 __
- $a ok $b bmc $g 2196408 $s 1229880
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 15 $c 9 $d 1865-1892 $e 20240711 $i 1869-6953 $m Diabetes therapy $n Diabetes Ther $x MED00194311
- LZP __
- $a Pubmed-20241008
